For the better part of three years, AI in pharma commercial was the topic of every conference and the focus of almost no budgets. Pilot fatigue was real. Teams ran experiments, presented learnings, and then watched the work sit on a shelf while the next shiny object arrived. 2026 is different — and I'd argue the gap between companies that have moved to production and those still in perpetual "explore mode" is the most consequential strategic divide in life sciences commercialization right now.
What Changed
Three forces converged. First, the technology itself reached a threshold of reliability that makes enterprise deployment feasible. Models hallucinate less, integrate better with structured data, and can operate within the compliance guardrails that pharma requires. Second, the regulatory environment started catching up — guidance from FDA and EMA on AI-generated content and AI-assisted decision-making gave legal and medical-regulatory teams enough to work with. Third — and most importantly — a cohort of early movers demonstrated real commercial results, not just proof-of-concepts.
The question is no longer whether AI belongs in your commercial model. It's whether you're building it fast enough to matter.
Where the Leaders Are Winning
The companies I'm seeing pull ahead are doing three things consistently. They've identified a small number of high-value AI use cases and resourced them properly — not spread thin across a dozen experiments. They've invested in the underlying data infrastructure that makes AI outputs actually reliable. And they've built internal capability, not just vendor dependency.
The highest-impact applications I'm seeing in commercial right now: next-best-action systems that meaningfully improve field force effectiveness; GenAI-powered content engines that compress the medical-legal-regulatory review cycle; predictive models that identify patient populations earlier in the diagnosis-to-treatment journey; and AI-augmented competitive intelligence that gives brand teams real-time strategic input rather than quarterly reports.
Where Most Companies Still Are
Honestly? Running pilots. Or worse — having run a pilot, declared success on the learning (not the outcome), and moved on. The trap is organizational: AI initiatives that live in IT or digital innovation functions, disconnected from the commercial teams who would actually use and benefit from them. Without commercial ownership, these initiatives rarely reach scale.
There's also the data problem. AI is only as good as what it's trained and grounded on. Most pharma companies have commercially relevant data scattered across CRM systems, market research repositories, claims databases, and disconnected marketing platforms — none of it rationalized into a coherent commercial data asset. Solving for AI without solving for data is building on sand.
What to Do About It
If you're behind, the path forward isn't to try to do everything at once. It's to be ruthlessly selective. Pick one or two use cases where AI can create measurable commercial value — ideally where you already have reasonable data coverage — and drive those to production. Learn what it takes to govern AI outputs in your regulatory environment. Build the internal muscle. Then expand.
The companies that win the next five years in life sciences commercialization won't necessarily be the ones that started AI earliest. They'll be the ones that moved from experimentation to execution fastest — and built organizations that can keep learning as the technology evolves.
That's the gap worth briidjing.
Want to talk through where AI fits in your commercial strategy?
I work with pharma and biotech teams to identify high-value AI use cases, design the roadmap, and navigate the organizational realities of making it real.
Get in touch →